M/XDR-TB in Europa Christoph Lange Tuberkulose in der EU La C La La ECDC 2015 Antibiotikaresistenz von M. tuberculosis Definition der M/XDR-TB Multiresistenz MDR Extensive Resistenz XDR Resistenz gegen mindestens - Rifampicin - Isoniazid Complicated treatment. Duration of treatment is prolonged to > 18 months Outcome depends on level of drug resistance MDR plus Resistenz gegen - mind. 1 Fluorochinolon - Amikacin, Capreomycin oder Kanamycin Complicated treatment. Duration of treatment is prolonged to > 24 months Outcome depends on level of drug resistance Bekannte Patienten mit MDR-TB - weltweit Region 2009 2010 2011 2012 2013 Afrika 10.741 9.340 12.384 18.129 32.480 N/S America 2.884 2.661 3.474 2.967 3.362 496 873 841 2.236 3.687 Europe 28.157 33.776 34.199 36.708 45.136 S/E Asia 2.560 3.942 6.615 19.202 40.335 W-Pacific 2.059 4.295 4.394 4.473 11.412 total 46.897 54.887 61.907 83.715 136.412 East Med. Global Tuberculosis Report WHO 2014 Bekannte Patienten mit MDR-TB - weltweit Region 2009 2010 2011 2012 2013 Afrika 10.741 9.340 12.384 18.129 32.480 N/S America 2.884 2.661 3.474 2.967 3.362 496 873 841 2.236 3.687 Europe 28.157 33.776 34.199 36.708 45.136 S/E Asia 2.560 3.942 6.615 19.202 40.335 W-Pacific 2.059 4.295 4.394 4.473 11.412 total 46.897 54.887 61.907 83.715 136.412 East Med. Global Tuberculosis Report WHO 2014 MDR-TB in Europa ECDC Surveillance Report 2015 Antibiotikaresistenz jenseits von MDR-TB - in Europa - Günther G et al. Emerg Infect Dis 2015 Antibiotikaresistenz jenseits von MDR-TB - in Europa - Günther G et al. Emerg Infect Dis 2015 Antibiotikaresistenz jenseits von MDR-TB - in Europa - Günther G et al. Emerg Infect Dis 2015 Antibiotikaresistenz jenseits von MDR-TB - in Europa - Günther G et al. Emerg Infect Dis 2015 Antibiotikaresistenz jenseits von MDR-TB - in Europa - Günther G et al. Emerg Infect Dis 2015 Antibiotikaresistenz jenseits von MDR-TB - in Europa - Günther G et al. Emerg Infect Dis 2015 15/27 der MDR-TB Hochprävalenz-Länder liegen in der Europa-Region der WHO Data for 2013 % new cases with MDR-TB % retreatment cases with MDR-TB Total number of patients with MDR-TB Belarus 35 55 1386 Kyrgyzstan 26 55 1191 Kazakhstan 25 55 6411 R Moldova 24 62 939 Uzbekistan 23 62 5751 Russia 19 49 13521 Estonia 17 48 54 Ukraine 14 32 10585 Azerbaijan 13 28 1043 Tajikistan 13 56 2084 Georgia 11 38 406 Lituania 11 44 256 Armenia 9.4 43 119 Latvia 8.8 26 82 Bulgaria 2.3 62 37 Global Tuberculosis Report WHO 2014 15/27 der MDR-TB Hochprävalenz-Länder liegen in der Europa-Region der WHO Data for 2013 % new cases with MDR-TB % retreatment cases with MDR-TB Total number of patients with MDR-TB Belarus 35 55 1386 Kyrgyzstan 26 55 1191 Kazakhstan 25 55 6411 R Moldova 24 62 939 Uzbekistan 23 62 5751 Russia 19 49 13521 Estonia 17 48 54 Ukraine 14 32 10585 Azerbaijan 13 28 1043 Tajikistan 13 56 2084 Georgia 11 38 406 Lituania 11 44 256 Armenia 9.4 43 119 Latvia 8.8 26 82 Bulgaria 2.3 62 37 Global Tuberculosis Report WHO 2014 Kosten der TB Therapie Günther G et al. Eur Respir J. 2015 Kosten der TB Therapie pan susceptible MDR pre XDR (inj) pre XDR (fq) XDR Günther G et al. Eur Respir J. 2015 www.tb-net.org
© Copyright 2024 ExpyDoc
